By Counterforce Health Team in Zokinvy (lonafarnib) —

How to Get Zokinvy (lonafarnib) Covered by Aetna (CVS Health) in Pennsylvania: Complete Prior Authorization & Appeals Guide

Answer Box: Getting Zokinvy Covered by Aetna in Pennsylvania

Zokinvy (lonafarnib) requires prior authorization from Aetna (CVS Health) for HGPS and progeroid laminopathies. Key requirements: genetic testing confirming LMNA/ZMPSTE24 mutations, BSA ≥0.39 m², age ≥12 months, and specialist consultation. First step: Contact your geneticist or pediatric cardiologist to initiate the PA process through Aetna's provider portal. If denied, Pennsylvania's new Independent External Review Program has overturned 50% of appealed denials in 2024, giving you strong recourse.

Table of Contents

  1. Plan Types & Network Requirements
  2. Formulary Status & Tier Placement
  3. Prior Authorization Requirements
  4. Specialty Pharmacy & Dispensing
  5. Step-by-Step: Fastest Path to Approval
  6. Common Denial Reasons & Solutions
  7. Appeals Process in Pennsylvania
  8. Cost Considerations

Plan Types & Network Requirements

Aetna offers several plan types in Pennsylvania, each with different implications for accessing Zokinvy:

HMO Plans: Require a primary care physician (PCP) referral to see genetics specialists. Your PCP must refer you to an in-network geneticist or pediatric cardiologist before Zokinvy can be prescribed.

PPO Plans: Allow direct access to specialists without referrals, but you'll pay less when using in-network providers. Most genetics centers in Pennsylvania accept Aetna PPO.

EPO Plans: Cover only in-network providers but don't require referrals. Verify your genetics specialist is in-network before your appointment.

Note: All Aetna plan types in Pennsylvania require prior authorization for Zokinvy, regardless of your network status.

Formulary Status & Tier Placement

Zokinvy is classified as a non-preferred specialty medication (Tier 4) on most Aetna formularies. This placement means:

  • Higher out-of-pocket costs compared to preferred medications
  • Mandatory specialty pharmacy dispensing
  • Prior authorization required for all patients
  • No generic alternatives available

The medication is not subject to step therapy requirements, as there are no equivalent alternatives for HGPS treatment.

Prior Authorization Requirements

Coverage at a Glance

Requirement What It Means Where to Find It
Genetic Testing LMNA or ZMPSTE24 mutations confirmed Lab report from certified genetics lab
Age Minimum Patient ≥12 months old Medical records
BSA Requirement Body surface area ≥0.39 m² Current height/weight calculation
Specialist Oversight Geneticist or pediatric cardiologist Consultation notes
Diagnosis Codes E34.8 (progeria-like syndromes) Medical records

Required Documentation

Your healthcare provider must submit:

  1. Genetic test results confirming pathogenic LMNA or ZMPSTE24 mutations
  2. Specialist consultation notes from geneticist or pediatric cardiologist
  3. BSA calculation with current height and weight measurements
  4. Medical necessity letter addressing FDA-approved indication
  5. Complete clinical history demonstrating characteristic HGPS features
  6. ICD-10 diagnosis code E34.8 for progeria-like syndromes

Specialty Pharmacy & Dispensing

Zokinvy must be dispensed through CVS Specialty Pharmacy, Aetna's preferred specialty partner. Key details:

  • Quantity limit: 120 capsules per 30 days
  • Automatic enrollment once PA is approved
  • Direct-to-patient shipping available
  • Clinical support included with dispensing

Your prescriber will coordinate with CVS Specialty after PA approval. Patients receive setup calls to arrange delivery and review administration instructions.

Step-by-Step: Fastest Path to Approval

1. Confirm Genetic Testing (Patient/Family)

Ensure you have genetic test results confirming LMNA or ZMPSTE24 mutations. If testing hasn't been done, request it from your genetics specialist. Timeline: 2-4 weeks for results

2. Schedule Specialist Consultation (Patient)

Book an appointment with a geneticist or pediatric cardiologist experienced in HGPS management. Timeline: 1-3 weeks depending on availability

3. Gather Clinical Documentation (Clinic Staff)

Collect genetic test reports, growth charts, cardiac evaluations, and previous treatment records. Timeline: 1-2 days

4. Submit Prior Authorization (Provider)

Provider submits PA through Aetna's online portal with all required documentation. Timeline: Same day submission

5. Follow Up on Status (Clinic/Patient)

Check PA status after 3-5 business days. Standard review takes up to 15 business days. Timeline: 15 business days maximum

6. Set Up Specialty Pharmacy (Patient)

Once approved, CVS Specialty will contact you to arrange dispensing and delivery. Timeline: 24-48 hours after approval

7. Begin Treatment (Patient)

Start Zokinvy as prescribed, with ongoing specialist monitoring. Timeline: Within days of pharmacy setup

Common Denial Reasons & Solutions

Denial Reason How to Overturn
Missing genetic confirmation Submit certified lab report showing LMNA/ZMPSTE24 mutations
Insufficient specialist documentation Provide detailed consultation notes from geneticist or pediatric cardiologist
BSA below threshold Recalculate current BSA; if still <0.39 m², document expected growth trajectory
"Not medically necessary" Submit medical necessity letter citing FDA approval and clinical guidelines
Age requirement not met Confirm patient is ≥12 months; provide birth certificate if needed

Appeals Process in Pennsylvania

Pennsylvania offers one of the strongest patient appeal systems in the country. If Aetna denies your Zokinvy request:

Internal Appeal (First Step)

  • Deadline: 180 days from denial date
  • Timeline: 30 days for standard review, 72 hours for expedited
  • How to file: Call Aetna member services or submit through online portal
  • Required: Copy of denial letter, additional medical records

Pennsylvania Independent External Review

Pennsylvania's new external review program, launched in 2024, has overturned 50% of appealed denials.

Eligibility: Available for commercial insurance (not self-funded employer plans) Deadline: 4 months after receiving "Final Adverse Benefit Determination" Cost: Free to patients Timeline: 45 days for standard review, 72 hours for expedited Success rate: 50.1% of appeals overturned in first year

To request external review:

  1. Complete Aetna's internal appeal process first
  2. Submit request to Pennsylvania Insurance Department
  3. Include denial letters, medical records, and supporting documentation
  4. Submit additional evidence within 15 days if requested

Contact: Pennsylvania Insurance Department at 1-877-881-6388 or visit pa.gov external review portal.

Clinician Corner: Medical Necessity Letter Checklist

When drafting your medical necessity letter, include:

  • Patient presentation: Age, confirmed genetic diagnosis, characteristic HGPS features
  • Clinical rationale: FDA approval for mortality risk reduction in HGPS
  • Dosing justification: Weight-based dosing per FDA labeling
  • Monitoring plan: Ongoing specialist oversight, growth tracking, cardiac monitoring
  • Alternative considerations: Why supportive care alone is insufficient

Key citation: Reference FDA approval based on clinical trials showing mortality benefit in HGPS patients.

Cost Considerations

Zokinvy is expensive, with typical costs around $90,000 monthly. Cost-sharing varies by plan:

  • Deductible: May apply before coverage begins
  • Coinsurance: Typically 20-40% for Tier 4 specialty medications
  • Out-of-pocket maximum: Provides annual cost protection

Manufacturer support: Eiger BioPharmaceuticals offers patient assistance programs. Contact them directly for eligibility requirements.

When to Escalate

Contact Pennsylvania regulators if:

  • Aetna delays exceed published timelines
  • Required forms are unavailable
  • Internal appeals are improperly handled

Pennsylvania Insurance Department Consumer Services: 1-877-881-6388

FAQ

Q: How long does Aetna's prior authorization take in Pennsylvania? A: Standard PA decisions take up to 15 business days. Expedited reviews (for medical urgency) are completed within 72 hours.

Q: What if my genetics specialist isn't in Aetna's network? A: Request a network exception if no in-network specialists are available within reasonable distance. Aetna must provide access to necessary specialists.

Q: Can I appeal if I'm on a self-funded employer plan? A: Self-funded plans aren't eligible for Pennsylvania's external review program, but you can still pursue internal appeals and federal external review through your plan.

Q: Does step therapy apply to Zokinvy? A: No, there are no equivalent alternatives for HGPS treatment, so step therapy doesn't apply.

Q: What happens if my PA expires? A: Begin renewal 60 days before expiration. You'll need updated clinical assessments and current BSA calculations.

About Counterforce Health: Counterforce Health specializes in turning insurance denials into successful appeals for complex medications like Zokinvy. Our platform helps patients and clinicians navigate prior authorization requirements by analyzing denial letters, plan policies, and clinical notes to create targeted, evidence-backed appeals. We understand the unique challenges of getting rare disease medications approved and provide the documentation and advocacy support needed for success. Visit www.counterforcehealth.org to learn more about our services.

When facing a Zokinvy denial, Counterforce Health can help you build a stronger appeal by identifying the specific denial reasons and crafting point-by-point rebuttals aligned with Aetna's own coverage policies.

Sources & Further Reading

Disclaimer: This information is for educational purposes only and does not constitute medical or legal advice. Coverage policies vary by plan and employer. Always verify current requirements with Aetna member services and consult with your healthcare provider about treatment decisions. For personalized assistance with Pennsylvania insurance appeals, contact the Pennsylvania Insurance Department Consumer Services at 1-877-881-6388.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.